UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
January 24, 2005
Commission File Number 0-21392
AMARIN CORPORATION PLC
(Translation of registrant's name into English)
7 Curzon Street
London W1J 5HG
England
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
Attachment:
Material Events
(a) Amarin Corporation announces appointment of non-executive directors.
This report on Form 6-K is hereby incorporated by reference
in (a) the registration statement on Form F-3 (Registration No.
333-104748) of Amarin Corporation plc and in the prospectus
contained therein, (b) the registration statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc and in the
prospectus contained therein, (c) the registration statement on
Form F-3 (Registration No. 333-12642) of Amarin Corporation plc and
in the prospectus contained therein, (d) the registration statement
on Form F-3 (Registration No. 333-121431) of Amarin Corporation plc and
in the prospectus contained therein and (e) the registration statement
on Form F-3 (Registration No. 333-121760) of Amarin Corporation plc and
in the prospectus contained therein,, and this report on Form 6-K
shall be deemed a part of each such registration statement from the
date on which this report is filed, to the extent not superseded by
documents or reports subsequently filed or furnished by Amarin
Corporation plc under the Securities Act of 1933 or the Securities
Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By: /s/ ALAN COOKE
Name: Alan Cooke
Title: Chief Financial Officer
Date: January 24, 2005
EXHIBIT INDEX
Index to Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material event description 4
Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com
Alan Cooke
Chief Financial Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com
AMARIN CORPORATION PLC APPOINTS SIMON KUKES AND MICHAEL WALSH AS DIRECTORS
LONDON, United Kingdom, January 24, 2005 - Amarin Corporation plc (NASDAQSC:
AMRN), the UK-based neuroscience pharmaceutical company, today announced the
appointment of Simon Kukes and Michael Walsh as non-executive directors.
Thomas Lynch, chairman of Amarin, said:
"We are privileged that businessmen of this caliber and experience are joining
Amarin's board at this pivotal time as we progress the clinical development of
Miraxion(TM), our exciting compound which we believe has the potential to
improve the lives of thousands of Huntington's disease sufferers. Dr Kukes and
Dr Walsh have been exemplary business leaders for many years and both possess a
distinguished academic background."
Simon Kukes
Dr Kukes is an American citizen. He was President and Chief Executive of Tyumen
Oil Company (TNK) from 1998 until its merger with British Petroleum (BP) in
2003. He then joined Yukos Oil as chairman. He also served as chief executive of
Yukos in 2003 until June 2004. In 1999, he was voted one of the Top 10 Central
European Executives by the Wall Street Journal Europe and in 2003 he was named
by The Financial Times and PricewaterhouseCoopers as one of the 64 most
respected business leaders in the world. He owns approximately 8% of the
ordinary stock in Amarin.
Dr Kukes has a primary degree in Chemical Engineering from the Institute for
Chemical Technology, Moscow and a PhD in Physical Chemistry from the Academy of
Sciences, Moscow and was a Post-Doctoral Fellow of Rice University, Houston,
Texas. He is the holder of more than 130 patents and has published more than 60
scientific papers. He is currently a member of the Council of Energy, Marine
Transportation and Public Policy at Columbia University in New York.
Michael Walsh
Dr Walsh is executive director of International Investment and Underwriting
("IIU"), a private equity firm based in Dublin with numerous international
investments. Dr Walsh is Chairman of Irish Nationwide Building Society, one of
Ireland's largest financial institutions. He is a non-executive director of a
number of companies including London City Airport, Daon, a company involved in
biometric authentication and Seer Partners, a technology oriented venture
capital company.
Dr. Walsh has BComm and MBS degrees from University College Dublin and MBA and
PhD degrees from the Wharton School, University of Pennsylvania. Prior to IIU,
he was an executive director of NCB Group Ltd, one of Ireland's leading
stockbrokers. He was previously Professor of Banking and Finance at University
College Dublin.
About Amarin Corporation
Amarin Corporation is a neuroscience pharmaceutical company based in London and
in Stirling, Scotland, focused on the development and commercialisation of novel
drugs for the treatment of neurological disorders affecting the central nervous
system. Miraxion, Amarin's lead compound, has completed one Phase III clinical
trial for the treatment of Huntington's disease, a fatal genetic
neurodegenerative disease causing dementia, chorea and impairment of voluntary
movement resulting in the progressive loss of independence.
The company is currently finalising the protocols for a further two Phase III
clinical trials of Miraxion. In addition, the company recently announced
positive data analysis from two exploratory Phase II clinical studies on the use
of Miraxion to treat depression.
On October 1 last, Thomas Lynch, Amarin's chairman, announced that he had
purchased a 25% interest in Amarin previously owned by Elan Corporation plc. On
October 7, the company announced that it had raised $12.75 million through a
private placing. Amarin stock trades on NASDAQSC (ticker: AMRN) and there are
approximately 38 million shares issued.
For press releases and other corporate information, visit our website at
http://www.amarincorp.com.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause the
Company's actual results in future periods to be materially different from any
performance suggested herein. Such risks and uncertainties include, without
limitation, the uncertainty of entering into and consummating a definitive
agreement on terms acceptable to the parties, the inherent uncertainty of
pharmaceutical research, product development and commercialization, the impact
of competitive products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more information, please
refer to Amarin Corporation's Annual Report for 2003 on Form 20-F and its Form
6-Ks as filed with the U.S. Securities and Exchange Commission. The company
assumes no obligation to update information on its expectations.